Bicara Therapeutics (NASDAQ:BCAX) Now Covered by Analysts at Citizens Jmp

Citizens Jmp assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report report published on Thursday morning, Marketbeat.com reports. The firm issued a market perform rating and a $31.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Mizuho raised Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Finally, Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Bicara Therapeutics Trading Up 1.9%

NASDAQ BCAX opened at $16.91 on Thursday. The stock has a market capitalization of $926.33 million, a price-to-earnings ratio of -7.55 and a beta of -0.79. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $19.71. The stock has a 50-day moving average of $17.54 and a 200 day moving average of $14.84.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.12). Equities analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bicara Therapeutics news, insider David Raben sold 5,500 shares of Bicara Therapeutics stock in a transaction on Monday, November 24th. The stock was sold at an average price of $18.45, for a total value of $101,475.00. Following the sale, the insider owned 35,497 shares in the company, valued at $654,919.65. The trade was a 13.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Claire Mazumdar sold 41,163 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $18.86, for a total value of $776,334.18. Following the transaction, the chief executive officer owned 309,892 shares of the company’s stock, valued at approximately $5,844,563.12. This represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 95,922 shares of company stock valued at $1,784,142. Insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BCAX. Vestal Point Capital LP increased its position in shares of Bicara Therapeutics by 2.0% during the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after acquiring an additional 100,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Bicara Therapeutics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after purchasing an additional 195,667 shares during the period. Millennium Management LLC increased its holdings in Bicara Therapeutics by 37.0% in the 3rd quarter. Millennium Management LLC now owns 1,014,892 shares of the company’s stock valued at $16,025,000 after purchasing an additional 273,873 shares during the last quarter. Geode Capital Management LLC increased its holdings in Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after purchasing an additional 180,833 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its position in Bicara Therapeutics by 91.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 504,085 shares of the company’s stock valued at $7,959,000 after purchasing an additional 241,334 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.